NVTA Stock Recent News

– Program provides accessible and affordable testing for pediatric epilepsy patients – – Genetic and clinical insights from test results to strengthen Invitae's rare disease database – SAN FRANCISCO , July 22, 2024  /PRNewswire/ -- Invitae  (OTC: NVTAQ), a leading medical genetics company, today announced the launch of its Unlock™ Behind the Seizure® program, which provides accessible and affordable genetic testing for pediatric epilepsy patients in the hopes of shortening the diagnostic odyssey and enabling a path towards effective, personalized care and precision therapy1. Millions of people worldwide live with epilepsy and more than half of epilepsies are caused by genetic abnormalities.

Softbank-backed genetic test maker Invitae said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy court and intends to pursue a sale process.

Invitae (NYSE: NVTA ) stock fell as much as 78% yesterday before it was ultimately halted because undisclosed news about the firm was pending. Many investors now expect that the SoftBank (OTCMKTS: SFTBY ) backed genetic testing specialist will file for bankruptcy before the end of this week.

Medical genetics firm Invitae (NYSE: NVTA ) suffered a shocking fall from grace as insider reports point to an upcoming bankruptcy filing. Although the company forwarded a compelling concept — leveraging genetic testing and diagnostics to assess hereditary disease risks — the business model didn't resonate with customers or investors.

Medical test maker Invitae is preparing to file for bankruptcy within weeks, the Wall Street Journal reported on Monday, according to people familiar with the matter.

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges.

Invitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Chinese stocks are up today and investors wondering why can find out all about these movements with our coverage for Friday! All of this comes from recent data concerning the Chinese economy.

Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals.